Stem definition | Drug id | CAS RN |
---|---|---|
1920 | 54-11-5 |
Dose | Unit | Route |
---|---|---|
30 | mg | Chewing gum |
60 | mg | Inhal |
30 | mg | N |
30 | mg | SL |
14 | mg | TD |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 16.70 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.52 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 2.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 18 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.95 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 7, 1991 | FDA | SANOFI AVENTIS US |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Macular degeneration | 647.67 | 13.56 | 233 | 16092 | 18675 | 56257067 |
Nicotine dependence | 581.78 | 13.56 | 110 | 16215 | 598 | 56275144 |
Drug withdrawal syndrome neonatal | 284.97 | 13.56 | 74 | 16251 | 1942 | 56273800 |
Drug dependence | 250.86 | 13.56 | 125 | 16200 | 22408 | 56253334 |
Foetal exposure during pregnancy | 211.04 | 13.56 | 128 | 16197 | 33695 | 56242047 |
Incorrect product administration duration | 205.95 | 13.56 | 86 | 16239 | 10240 | 56265502 |
Premature delivery | 204.64 | 13.56 | 116 | 16209 | 26944 | 56248798 |
Product adhesion issue | 186.79 | 13.56 | 64 | 16261 | 4419 | 56271323 |
Overdose | 180.56 | 13.56 | 186 | 16139 | 105644 | 56170098 |
Maternal exposure during pregnancy | 113.92 | 13.56 | 200 | 16125 | 189353 | 56086389 |
Myocardial stunning | 101.51 | 13.56 | 20 | 16305 | 139 | 56275603 |
Rheumatoid arthritis | 84.95 | 13.56 | 7 | 16318 | 382597 | 55893145 |
Application site erythema | 84.00 | 13.56 | 36 | 16289 | 4564 | 56271178 |
Intentional product misuse | 83.17 | 13.56 | 88 | 16237 | 51416 | 56224326 |
Jaundice neonatal | 81.24 | 13.56 | 23 | 16302 | 840 | 56274902 |
Dependence | 81.20 | 13.56 | 28 | 16297 | 1969 | 56273773 |
Accidental overdose | 80.24 | 13.56 | 58 | 16267 | 20403 | 56255339 |
Application site pruritus | 73.42 | 13.56 | 31 | 16294 | 3788 | 56271954 |
Drug abuse | 71.55 | 13.56 | 93 | 16232 | 67517 | 56208225 |
Poor feeding infant | 70.05 | 13.56 | 16 | 16309 | 240 | 56275502 |
Necrosis ischaemic | 68.92 | 13.56 | 20 | 16305 | 799 | 56274943 |
Product quality issue | 67.48 | 13.56 | 63 | 16262 | 31673 | 56244069 |
Rhesus incompatibility | 67.21 | 13.56 | 13 | 16312 | 81 | 56275661 |
Rib deformity | 66.90 | 13.56 | 15 | 16310 | 206 | 56275536 |
Premature baby | 65.37 | 13.56 | 50 | 16275 | 19155 | 56256587 |
Chronic sinusitis | 60.83 | 13.56 | 35 | 16290 | 8343 | 56267399 |
Tobacco abuse | 59.57 | 13.56 | 17 | 16308 | 639 | 56275103 |
Exposure during pregnancy | 58.64 | 13.56 | 125 | 16200 | 136217 | 56139525 |
Pneumonia streptococcal | 58.44 | 13.56 | 21 | 16304 | 1667 | 56274075 |
Oligohydramnios | 54.38 | 13.56 | 29 | 16296 | 5965 | 56269777 |
Beta haemolytic streptococcal infection | 52.46 | 13.56 | 20 | 16305 | 1874 | 56273868 |
Paraesthesia oral | 52.23 | 13.56 | 39 | 16286 | 14410 | 56261332 |
Chronic obstructive pulmonary disease | 50.17 | 13.56 | 72 | 16253 | 57343 | 56218399 |
Maternal exposure during breast feeding | 48.90 | 13.56 | 23 | 16302 | 3624 | 56272118 |
Low birth weight baby | 45.05 | 13.56 | 26 | 16299 | 6232 | 56269510 |
Procedural pain | 41.90 | 13.56 | 36 | 16289 | 16235 | 56259507 |
Nasal obstruction | 41.20 | 13.56 | 15 | 16310 | 1236 | 56274506 |
Arthropathy | 40.91 | 13.56 | 5 | 16320 | 200270 | 56075472 |
Alopecia | 40.87 | 13.56 | 17 | 16308 | 293441 | 55982301 |
Reversible airways obstruction | 39.72 | 13.56 | 15 | 16310 | 1369 | 56274373 |
Treatment noncompliance | 39.46 | 13.56 | 48 | 16277 | 32575 | 56243167 |
Exposure via breast milk | 39.19 | 13.56 | 16 | 16309 | 1796 | 56273946 |
Throat clearing | 38.26 | 13.56 | 15 | 16310 | 1515 | 56274227 |
Application site rash | 37.87 | 13.56 | 17 | 16308 | 2406 | 56273336 |
Application site reaction | 37.40 | 13.56 | 12 | 16313 | 674 | 56275068 |
Congenital tricuspid valve incompetence | 36.83 | 13.56 | 8 | 16317 | 94 | 56275648 |
Anxiety | 34.78 | 13.56 | 129 | 16196 | 193043 | 56082699 |
Congenital pulmonary hypertension | 34.55 | 13.56 | 7 | 16318 | 57 | 56275685 |
Joint swelling | 34.04 | 13.56 | 21 | 16304 | 289779 | 55985963 |
Systemic lupus erythematosus | 33.31 | 13.56 | 6 | 16319 | 180072 | 56095670 |
Substance abuse | 33.10 | 13.56 | 19 | 16306 | 4506 | 56271236 |
Drug ineffective | 32.02 | 13.56 | 406 | 15919 | 918583 | 55357159 |
Treatment failure | 30.82 | 13.56 | 6 | 16319 | 170386 | 56105356 |
Therapeutic product effect decreased | 30.58 | 13.56 | 6 | 16319 | 169446 | 56106296 |
Toxicity to various agents | 30.17 | 13.56 | 137 | 16188 | 224427 | 56051315 |
Developmental hip dysplasia | 29.81 | 13.56 | 12 | 16313 | 1299 | 56274443 |
Premature separation of placenta | 29.60 | 13.56 | 13 | 16312 | 1747 | 56273995 |
Sputum purulent | 29.33 | 13.56 | 11 | 16314 | 985 | 56274757 |
Arthralgia | 29.14 | 13.56 | 64 | 16261 | 501605 | 55774137 |
Fatigue | 29.13 | 13.56 | 124 | 16201 | 788428 | 55487314 |
Reversible cerebral vasoconstriction syndrome | 28.85 | 13.56 | 14 | 16311 | 2363 | 56273379 |
Caesarean section | 28.66 | 13.56 | 29 | 16296 | 16062 | 56259680 |
Maternal drugs affecting foetus | 28.49 | 13.56 | 18 | 16307 | 5075 | 56270667 |
Agitation neonatal | 28.25 | 13.56 | 9 | 16316 | 494 | 56275248 |
Drug intolerance | 27.39 | 13.56 | 22 | 16303 | 264796 | 56010946 |
Dysmetropsia | 27.28 | 13.56 | 6 | 16319 | 75 | 56275667 |
Contraindicated product administered | 27.22 | 13.56 | 10 | 16315 | 186276 | 56089466 |
Application site irritation | 27.13 | 13.56 | 12 | 16313 | 1640 | 56274102 |
Secondary immunodeficiency | 26.99 | 13.56 | 11 | 16314 | 1229 | 56274513 |
Axonal neuropathy | 26.15 | 13.56 | 10 | 16315 | 945 | 56274797 |
Loss of proprioception | 25.91 | 13.56 | 8 | 16317 | 396 | 56275346 |
Full blood count abnormal | 25.81 | 13.56 | 35 | 16290 | 26427 | 56249315 |
Xanthogranuloma | 24.92 | 13.56 | 4 | 16321 | 6 | 56275736 |
Chest X-ray abnormal | 24.32 | 13.56 | 15 | 16310 | 4055 | 56271687 |
Abnormal dreams | 24.13 | 13.56 | 21 | 16304 | 9628 | 56266114 |
Application site swelling | 23.43 | 13.56 | 8 | 16317 | 546 | 56275196 |
Symphysiolysis | 23.30 | 13.56 | 4 | 16321 | 11 | 56275731 |
Irritability | 22.81 | 13.56 | 35 | 16290 | 29553 | 56246189 |
Glossodynia | 22.58 | 13.56 | 8 | 16317 | 152450 | 56123292 |
Application site dermatitis | 22.55 | 13.56 | 6 | 16319 | 173 | 56275569 |
Premature labour | 22.24 | 13.56 | 22 | 16303 | 11860 | 56263882 |
Abortion induced | 22.15 | 13.56 | 20 | 16305 | 9625 | 56266117 |
Discomfort | 21.76 | 13.56 | 7 | 16318 | 141754 | 56133988 |
Rhinitis | 21.49 | 13.56 | 19 | 16306 | 8897 | 56266845 |
Drug screen positive | 21.29 | 13.56 | 13 | 16312 | 3451 | 56272291 |
Sneezing | 20.63 | 13.56 | 24 | 16301 | 15536 | 56260206 |
Infection | 20.23 | 13.56 | 17 | 16308 | 200189 | 56075553 |
Musculoskeletal stiffness | 20.19 | 13.56 | 10 | 16315 | 155997 | 56119745 |
Respiratory failure | 20.11 | 13.56 | 67 | 16258 | 94995 | 56180747 |
Swelling | 20.07 | 13.56 | 24 | 16301 | 239747 | 56035995 |
Abdominal discomfort | 19.94 | 13.56 | 31 | 16294 | 277243 | 55998499 |
Cardiac death | 19.76 | 13.56 | 7 | 16318 | 533 | 56275209 |
Application site vesicles | 19.51 | 13.56 | 9 | 16316 | 1356 | 56274386 |
False positive investigation result | 19.49 | 13.56 | 7 | 16318 | 555 | 56275187 |
Wound | 19.36 | 13.56 | 8 | 16317 | 138796 | 56136946 |
Hepatic enzyme increased | 19.31 | 13.56 | 13 | 16312 | 171371 | 56104371 |
Withdrawal syndrome | 18.89 | 13.56 | 25 | 16300 | 18437 | 56257305 |
Upper-airway cough syndrome | 18.65 | 13.56 | 18 | 16307 | 9420 | 56266322 |
Therapeutic product effect incomplete | 18.38 | 13.56 | 70 | 16255 | 105961 | 56169781 |
Oophoritis | 18.34 | 13.56 | 4 | 16321 | 48 | 56275694 |
Pre-eclampsia | 18.32 | 13.56 | 17 | 16308 | 8469 | 56267273 |
Suicidal ideation | 18.28 | 13.56 | 47 | 16278 | 57695 | 56218047 |
Nightmare | 17.55 | 13.56 | 23 | 16302 | 16803 | 56258939 |
Completed suicide | 17.46 | 13.56 | 81 | 16244 | 133752 | 56141990 |
Application site pain | 17.42 | 13.56 | 12 | 16313 | 3908 | 56271834 |
Megacolon | 17.38 | 13.56 | 9 | 16316 | 1742 | 56274000 |
Prinzmetal angina | 17.38 | 13.56 | 7 | 16318 | 759 | 56274983 |
Application site burn | 17.19 | 13.56 | 7 | 16318 | 780 | 56274962 |
Selective eating disorder | 16.67 | 13.56 | 9 | 16316 | 1895 | 56273847 |
Application site scar | 16.65 | 13.56 | 5 | 16320 | 225 | 56275517 |
Nasopharyngitis | 16.56 | 13.56 | 24 | 16301 | 220935 | 56054807 |
Loss of consciousness | 16.40 | 13.56 | 69 | 16256 | 109280 | 56166462 |
Condition aggravated | 16.14 | 13.56 | 49 | 16276 | 344849 | 55930893 |
Tobacco poisoning | 15.94 | 13.56 | 4 | 16321 | 91 | 56275651 |
Impaired healing | 15.82 | 13.56 | 3 | 16322 | 86838 | 56188904 |
Drug abuser | 15.73 | 13.56 | 10 | 16315 | 2849 | 56272893 |
Off label use | 15.61 | 13.56 | 96 | 16229 | 556084 | 55719658 |
Pain | 15.41 | 13.56 | 121 | 16204 | 663063 | 55612679 |
Antipsychotic drug level decreased | 15.12 | 13.56 | 5 | 16320 | 309 | 56275433 |
Diarrhoea | 15.07 | 13.56 | 116 | 16209 | 638391 | 55637351 |
Patent ductus arteriosus | 15.03 | 13.56 | 11 | 16314 | 3940 | 56271802 |
Mobility decreased | 14.99 | 13.56 | 5 | 16320 | 98986 | 56176756 |
Foetal growth restriction | 14.90 | 13.56 | 14 | 16311 | 7085 | 56268657 |
Peripheral swelling | 14.37 | 13.56 | 29 | 16296 | 234697 | 56041045 |
Tobacco interaction | 14.16 | 13.56 | 3 | 16322 | 31 | 56275711 |
Nervousness | 14.09 | 13.56 | 28 | 16297 | 28987 | 56246755 |
Blister | 14.05 | 13.56 | 7 | 16318 | 108880 | 56166862 |
Plethysmography | 13.99 | 13.56 | 3 | 16322 | 33 | 56275709 |
Foetal distress syndrome | 13.88 | 13.56 | 7 | 16318 | 1283 | 56274459 |
Drug withdrawal syndrome | 13.84 | 13.56 | 26 | 16299 | 25831 | 56249911 |
Sleep disorder due to a general medical condition | 13.72 | 13.56 | 15 | 16310 | 9075 | 56266667 |
Gastric dilatation | 13.70 | 13.56 | 6 | 16319 | 801 | 56274941 |
Hepatitis C | 13.65 | 13.56 | 12 | 16313 | 5574 | 56270168 |
Application site warmth | 13.61 | 13.56 | 4 | 16321 | 167 | 56275575 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nicotine dependence | 379.79 | 13.53 | 77 | 12942 | 423 | 31683902 |
Drug withdrawal syndrome neonatal | 300.93 | 13.53 | 94 | 12925 | 3398 | 31680927 |
Drug dependence | 274.76 | 13.53 | 149 | 12870 | 22430 | 31661895 |
Incorrect product administration duration | 227.02 | 13.53 | 80 | 12939 | 4222 | 31680103 |
Foetal exposure during pregnancy | 209.28 | 13.53 | 156 | 12863 | 40720 | 31643605 |
Intentional product misuse | 159.70 | 13.53 | 129 | 12890 | 37822 | 31646503 |
Overdose | 138.47 | 13.53 | 172 | 12847 | 84492 | 31599833 |
Accidental overdose | 133.59 | 13.53 | 87 | 12932 | 18263 | 31666062 |
Product adhesion issue | 118.69 | 13.53 | 38 | 12981 | 1487 | 31682838 |
Maternal exposure during breast feeding | 101.95 | 13.53 | 34 | 12985 | 1515 | 31682810 |
Premature baby | 99.20 | 13.53 | 72 | 12947 | 17994 | 31666331 |
Dependence | 84.06 | 13.53 | 27 | 12992 | 1067 | 31683258 |
Low birth weight baby | 76.43 | 13.53 | 43 | 12976 | 6927 | 31677398 |
Jaundice neonatal | 64.10 | 13.53 | 23 | 12996 | 1277 | 31683048 |
Alcohol abuse | 63.56 | 13.53 | 33 | 12986 | 4531 | 31679794 |
Foetal disorder | 62.27 | 13.53 | 20 | 12999 | 790 | 31683535 |
Toxicity to various agents | 60.03 | 13.53 | 187 | 12832 | 181300 | 31503025 |
Exposure via breast milk | 59.52 | 13.53 | 24 | 12995 | 1836 | 31682489 |
Tobacco poisoning | 58.83 | 13.53 | 10 | 13009 | 15 | 31684310 |
Neutropenia neonatal | 53.11 | 13.53 | 17 | 13002 | 664 | 31683661 |
Drug screen positive | 51.21 | 13.53 | 27 | 12992 | 3825 | 31680500 |
Poor feeding infant | 50.37 | 13.53 | 15 | 13004 | 459 | 31683866 |
Tremor neonatal | 48.65 | 13.53 | 14 | 13005 | 379 | 31683946 |
Drug abuser | 48.21 | 13.53 | 26 | 12993 | 3854 | 31680471 |
Alcohol interaction | 44.18 | 13.53 | 22 | 12997 | 2767 | 31681558 |
Tobacco abuse | 43.77 | 13.53 | 13 | 13006 | 394 | 31683931 |
Agitation neonatal | 38.23 | 13.53 | 15 | 13004 | 1068 | 31683257 |
Breech presentation | 36.23 | 13.53 | 9 | 13010 | 136 | 31684189 |
Body temperature abnormal | 35.65 | 13.53 | 12 | 13007 | 550 | 31683775 |
Application site pruritus | 35.46 | 13.53 | 15 | 13004 | 1295 | 31683030 |
Foetal distress syndrome | 35.19 | 13.53 | 14 | 13005 | 1034 | 31683291 |
Substance abuse | 33.63 | 13.53 | 26 | 12993 | 7132 | 31677193 |
Finnegan score increased | 32.48 | 13.53 | 6 | 13013 | 18 | 31684307 |
Drug use disorder | 31.72 | 13.53 | 20 | 12999 | 3963 | 31680362 |
Withdrawal syndrome | 31.59 | 13.53 | 31 | 12988 | 11686 | 31672639 |
Application site erythema | 31.39 | 13.53 | 16 | 13003 | 2113 | 31682212 |
Drug withdrawal syndrome | 30.39 | 13.53 | 38 | 12981 | 18712 | 31665613 |
Infant irritability | 29.89 | 13.53 | 6 | 13013 | 31 | 31684294 |
Drug abuse | 28.51 | 13.53 | 90 | 12929 | 87668 | 31596657 |
Laryngeal dysplasia | 27.19 | 13.53 | 4 | 13015 | 0 | 31684325 |
Application site reaction | 26.89 | 13.53 | 9 | 13010 | 405 | 31683920 |
Off label use | 26.79 | 13.53 | 65 | 12954 | 347209 | 31337116 |
Product quality issue | 26.67 | 13.53 | 33 | 12986 | 16078 | 31668247 |
Schizophrenia | 26.16 | 13.53 | 27 | 12992 | 10803 | 31673522 |
Infective exacerbation of chronic obstructive airways disease | 25.66 | 13.53 | 13 | 13006 | 1695 | 31682630 |
Regurgitation | 25.46 | 13.53 | 12 | 13007 | 1337 | 31682988 |
Venolymphatic malformation | 25.21 | 13.53 | 5 | 13014 | 24 | 31684301 |
Tobacco user | 24.43 | 13.53 | 9 | 13010 | 539 | 31683786 |
Product availability issue | 24.40 | 13.53 | 12 | 13007 | 1469 | 31682856 |
Tachycardia | 23.69 | 13.53 | 77 | 12942 | 76130 | 31608195 |
Floppy infant | 23.01 | 13.53 | 6 | 13013 | 111 | 31684214 |
Treatment noncompliance | 22.57 | 13.53 | 39 | 12980 | 25645 | 31658680 |
Oropharyngeal discomfort | 22.47 | 13.53 | 14 | 13005 | 2717 | 31681608 |
Vitamin B12 deficiency | 21.55 | 13.53 | 15 | 13004 | 3504 | 31680821 |
Application site rash | 21.39 | 13.53 | 9 | 13010 | 767 | 31683558 |
Acne infantile | 20.04 | 13.53 | 5 | 13014 | 77 | 31684248 |
Diarrhoea | 19.97 | 13.53 | 76 | 12943 | 352333 | 31331992 |
Application site scar | 19.56 | 13.53 | 4 | 13015 | 23 | 31684302 |
Renal hypoplasia | 19.47 | 13.53 | 5 | 13014 | 87 | 31684238 |
Neonatal hypoxia | 19.41 | 13.53 | 7 | 13012 | 394 | 31683931 |
Euphoric mood | 19.13 | 13.53 | 16 | 13003 | 4904 | 31679421 |
Palpitations | 18.87 | 13.53 | 43 | 12976 | 34540 | 31649785 |
Insomnia | 18.82 | 13.53 | 83 | 12936 | 94753 | 31589572 |
Potentiating drug interaction | 18.11 | 13.53 | 15 | 13004 | 4538 | 31679787 |
Pulmonary valve stenosis congenital | 17.42 | 13.53 | 5 | 13014 | 134 | 31684191 |
Application site vesicles | 17.30 | 13.53 | 7 | 13012 | 540 | 31683785 |
Antipsychotic drug level increased | 17.21 | 13.53 | 13 | 13006 | 3445 | 31680880 |
Nightmare | 17.17 | 13.53 | 23 | 12996 | 12114 | 31672211 |
Renal impairment | 17.14 | 13.53 | 7 | 13012 | 86342 | 31597983 |
Weight decrease neonatal | 16.79 | 13.53 | 6 | 13013 | 329 | 31683996 |
Adjustment disorder with mixed anxiety and depressed mood | 16.79 | 13.53 | 3 | 13016 | 7 | 31684318 |
Anxiety | 16.08 | 13.53 | 77 | 12942 | 90956 | 31593369 |
Emphysema | 15.95 | 13.53 | 19 | 13000 | 8899 | 31675426 |
Breathing-related sleep disorder | 15.93 | 13.53 | 5 | 13014 | 183 | 31684142 |
Necrotising ulcerative gingivostomatitis | 15.50 | 13.53 | 4 | 13015 | 71 | 31684254 |
Myoclonic epilepsy | 15.36 | 13.53 | 8 | 13011 | 1104 | 31683221 |
Application site urticaria | 15.34 | 13.53 | 4 | 13015 | 74 | 31684251 |
Agitation | 15.29 | 13.53 | 53 | 12966 | 54116 | 31630209 |
Hypersensitivity | 15.27 | 13.53 | 54 | 12965 | 55689 | 31628636 |
Eructation | 15.04 | 13.53 | 13 | 13006 | 4166 | 31680159 |
Application site discolouration | 15.03 | 13.53 | 5 | 13014 | 221 | 31684104 |
Drug tolerance increased | 14.86 | 13.53 | 6 | 13013 | 460 | 31683865 |
Neonatal disorder | 14.69 | 13.53 | 7 | 13012 | 799 | 31683526 |
Application site pain | 14.47 | 13.53 | 9 | 13010 | 1740 | 31682585 |
Death | 14.43 | 13.53 | 88 | 12931 | 360481 | 31323844 |
Chest pain | 13.98 | 13.53 | 89 | 12930 | 116868 | 31567457 |
Maternal drugs affecting foetus | 13.76 | 13.53 | 12 | 13007 | 3891 | 31680434 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nicotine dependence | 598.18 | 12.59 | 118 | 22528 | 741 | 70905057 |
Drug dependence | 472.75 | 12.59 | 233 | 22413 | 37088 | 70868710 |
Incorrect product administration duration | 341.75 | 12.59 | 129 | 22517 | 10695 | 70895103 |
Overdose | 265.45 | 12.59 | 298 | 22348 | 169447 | 70736351 |
Accidental overdose | 219.97 | 12.59 | 138 | 22508 | 34983 | 70870815 |
Intentional product misuse | 154.69 | 12.59 | 157 | 22489 | 79438 | 70826360 |
Application site erythema | 98.95 | 12.59 | 42 | 22604 | 4719 | 70901079 |
Myocardial stunning | 95.72 | 12.59 | 20 | 22626 | 173 | 70905625 |
Application site pruritus | 92.62 | 12.59 | 37 | 22609 | 3564 | 70902234 |
Product adhesion issue | 86.64 | 12.59 | 32 | 22614 | 2492 | 70903306 |
Toxicity to various agents | 86.34 | 12.59 | 293 | 22353 | 381879 | 70523919 |
Drug abuse | 83.25 | 12.59 | 160 | 22486 | 147096 | 70758702 |
Rheumatoid arthritis | 76.75 | 12.59 | 4 | 22642 | 291801 | 70613997 |
Alcohol abuse | 70.93 | 12.59 | 34 | 22612 | 5073 | 70900725 |
Substance abuse | 70.09 | 12.59 | 42 | 22604 | 9795 | 70896003 |
Necrosis ischaemic | 63.00 | 12.59 | 20 | 22626 | 984 | 70904814 |
Tobacco abuse | 61.08 | 12.59 | 19 | 22627 | 874 | 70904924 |
Drug abuser | 60.73 | 12.59 | 32 | 22614 | 5832 | 70899966 |
Dependence | 60.43 | 12.59 | 24 | 22622 | 2276 | 70903522 |
Rib deformity | 57.83 | 12.59 | 13 | 22633 | 163 | 70905635 |
Tobacco poisoning | 57.31 | 12.59 | 12 | 22634 | 105 | 70905693 |
Product quality issue | 53.41 | 12.59 | 57 | 22589 | 30504 | 70875294 |
Beta haemolytic streptococcal infection | 53.34 | 12.59 | 21 | 22625 | 1946 | 70903852 |
Macular degeneration | 53.26 | 12.59 | 32 | 22614 | 7496 | 70898302 |
Chronic sinusitis | 52.35 | 12.59 | 33 | 22613 | 8418 | 70897380 |
Application site reaction | 52.05 | 12.59 | 16 | 22630 | 707 | 70905091 |
Pneumonia streptococcal | 51.91 | 12.59 | 22 | 22624 | 2461 | 70903337 |
Application site rash | 46.03 | 12.59 | 19 | 22627 | 1990 | 70903808 |
Chronic obstructive pulmonary disease | 45.85 | 12.59 | 86 | 22560 | 77555 | 70828243 |
Product availability issue | 44.85 | 12.59 | 21 | 22625 | 2973 | 70902825 |
Paraesthesia oral | 42.58 | 12.59 | 37 | 22609 | 15380 | 70890418 |
Alcohol interaction | 41.51 | 12.59 | 23 | 22623 | 4630 | 70901168 |
Drug use disorder | 41.14 | 12.59 | 28 | 22618 | 8123 | 70897675 |
Premature delivery | 39.48 | 12.59 | 41 | 22605 | 21263 | 70884535 |
Application site irritation | 39.46 | 12.59 | 16 | 22630 | 1601 | 70904197 |
Withdrawal syndrome | 39.26 | 12.59 | 44 | 22602 | 24860 | 70880938 |
Drug screen positive | 39.20 | 12.59 | 24 | 22622 | 5816 | 70899982 |
Drug withdrawal syndrome | 38.77 | 12.59 | 50 | 22596 | 32665 | 70873133 |
Application site pain | 37.20 | 12.59 | 21 | 22625 | 4381 | 70901417 |
Anxiety | 37.16 | 12.59 | 154 | 22492 | 220176 | 70685622 |
Application site scar | 35.92 | 12.59 | 9 | 22637 | 184 | 70905614 |
Throat clearing | 35.24 | 12.59 | 15 | 22631 | 1696 | 70904102 |
Drug intolerance | 35.19 | 12.59 | 14 | 22632 | 225673 | 70680125 |
Treatment noncompliance | 33.16 | 12.59 | 56 | 22590 | 46518 | 70859280 |
Procedural pain | 32.19 | 12.59 | 34 | 22612 | 17975 | 70887823 |
Loss of consciousness | 32.10 | 12.59 | 116 | 22530 | 155600 | 70750198 |
Therapeutic product effect decreased | 31.96 | 12.59 | 4 | 22642 | 143014 | 70762784 |
Euphoric mood | 30.87 | 12.59 | 22 | 22624 | 6867 | 70898931 |
Nasal obstruction | 29.61 | 12.59 | 13 | 22633 | 1584 | 70904214 |
Reversible airways obstruction | 29.54 | 12.59 | 13 | 22633 | 1594 | 70904204 |
Reversible cerebral vasoconstriction syndrome | 28.79 | 12.59 | 15 | 22631 | 2670 | 70903128 |
Off label use | 28.10 | 12.59 | 132 | 22514 | 742928 | 70162870 |
Tachycardia | 26.86 | 12.59 | 111 | 22535 | 158435 | 70747363 |
Infective exacerbation of chronic obstructive airways disease | 26.85 | 12.59 | 14 | 22632 | 2497 | 70903301 |
Alopecia | 26.81 | 12.59 | 15 | 22631 | 198475 | 70707323 |
Schizoaffective disorder | 26.68 | 12.59 | 13 | 22633 | 2010 | 70903788 |
Maternal drugs affecting foetus | 26.08 | 12.59 | 12 | 22634 | 1632 | 70904166 |
Dysmetropsia | 26.01 | 12.59 | 6 | 22640 | 85 | 70905713 |
Arthropathy | 25.63 | 12.59 | 8 | 22638 | 150049 | 70755749 |
Application site vesicles | 25.20 | 12.59 | 11 | 22635 | 1322 | 70904476 |
Arthralgia | 25.06 | 12.59 | 80 | 22566 | 503310 | 70402488 |
Nightmare | 24.91 | 12.59 | 33 | 22613 | 22123 | 70883675 |
Application site urticaria | 24.57 | 12.59 | 7 | 22639 | 237 | 70905561 |
Joint swelling | 24.30 | 12.59 | 27 | 22619 | 253184 | 70652614 |
Body temperature abnormal | 24.25 | 12.59 | 12 | 22634 | 1917 | 70903881 |
Mental status changes | 23.51 | 12.59 | 58 | 22588 | 63043 | 70842755 |
Emphysema | 22.70 | 12.59 | 26 | 22620 | 15034 | 70890764 |
Sputum purulent | 22.54 | 12.59 | 10 | 22636 | 1250 | 70904548 |
Regurgitation | 22.48 | 12.59 | 12 | 22634 | 2244 | 70903554 |
Unresponsive to stimuli | 21.80 | 12.59 | 50 | 22596 | 51881 | 70853917 |
Application site dermatitis | 21.79 | 12.59 | 6 | 22640 | 179 | 70905619 |
Diarrhoea | 21.63 | 12.59 | 154 | 22492 | 783187 | 70122611 |
Exposure during pregnancy | 21.26 | 12.59 | 69 | 22577 | 87648 | 70818150 |
Renal impairment | 20.73 | 12.59 | 10 | 22636 | 143927 | 70761871 |
Application site discolouration | 20.59 | 12.59 | 8 | 22638 | 716 | 70905082 |
Maternal exposure during pregnancy | 20.51 | 12.59 | 82 | 22564 | 115263 | 70790535 |
Loss of proprioception | 20.47 | 12.59 | 8 | 22638 | 727 | 70905071 |
Schizophrenia | 20.45 | 12.59 | 26 | 22620 | 16742 | 70889056 |
Fatigue | 19.97 | 12.59 | 168 | 22478 | 824151 | 70081647 |
Vitamin B12 deficiency | 19.95 | 12.59 | 16 | 22630 | 5956 | 70899842 |
Infection | 19.65 | 12.59 | 23 | 22623 | 210762 | 70695036 |
Arteriosclerosis coronary artery | 19.55 | 12.59 | 25 | 22621 | 16190 | 70889608 |
Full blood count abnormal | 19.34 | 12.59 | 37 | 22609 | 33841 | 70871957 |
Pulmonary oedema | 19.29 | 12.59 | 64 | 22582 | 82214 | 70823584 |
Palpitations | 19.11 | 12.59 | 78 | 22568 | 110675 | 70795123 |
Oophoritis | 18.90 | 12.59 | 4 | 22642 | 37 | 70905761 |
Tobacco withdrawal symptoms | 18.61 | 12.59 | 3 | 22643 | 4 | 70905794 |
Axonal neuropathy | 18.42 | 12.59 | 10 | 22636 | 1934 | 70903864 |
Systemic lupus erythematosus | 18.19 | 12.59 | 5 | 22641 | 101897 | 70803901 |
Chest pain | 17.70 | 12.59 | 139 | 22507 | 251121 | 70654677 |
Derealisation | 17.68 | 12.59 | 9 | 22637 | 1527 | 70904271 |
Oropharyngeal discomfort | 17.62 | 12.59 | 15 | 22631 | 6064 | 70899734 |
Application site swelling | 17.51 | 12.59 | 7 | 22639 | 675 | 70905123 |
Drug ineffective | 17.16 | 12.59 | 205 | 22441 | 939547 | 69966251 |
Suicidal ideation | 17.09 | 12.59 | 55 | 22591 | 69541 | 70836257 |
Disease progression | 16.98 | 12.59 | 15 | 22631 | 156657 | 70749141 |
Nasopharyngitis | 16.96 | 12.59 | 28 | 22618 | 222178 | 70683620 |
Hepatocellular injury | 16.78 | 12.59 | 42 | 22604 | 46049 | 70859749 |
Intentional overdose | 16.72 | 12.59 | 69 | 22577 | 98366 | 70807432 |
Nervousness | 16.56 | 12.59 | 33 | 22613 | 31087 | 70874711 |
Chest discomfort | 16.49 | 12.59 | 81 | 22565 | 124300 | 70781498 |
Breathing-related sleep disorder | 16.40 | 12.59 | 5 | 22641 | 215 | 70905583 |
Foetal distress syndrome | 16.31 | 12.59 | 6 | 22640 | 462 | 70905336 |
Tobacco interaction | 16.24 | 12.59 | 4 | 22642 | 76 | 70905722 |
Xanthogranuloma | 15.95 | 12.59 | 4 | 22642 | 82 | 70905716 |
Hepatic enzyme increased | 15.88 | 12.59 | 16 | 22630 | 156974 | 70748824 |
Poor quality product administered | 15.77 | 12.59 | 11 | 22635 | 3320 | 70902478 |
Delirium | 15.71 | 12.59 | 56 | 22590 | 74558 | 70831240 |
Gastrointestinal disorder | 15.68 | 12.59 | 7 | 22639 | 105420 | 70800378 |
False positive investigation result | 15.65 | 12.59 | 7 | 22639 | 891 | 70904907 |
Potentiating drug interaction | 15.64 | 12.59 | 16 | 22630 | 8148 | 70897650 |
Myocarditis | 15.28 | 12.59 | 24 | 22622 | 18769 | 70887029 |
Cardiac death | 15.19 | 12.59 | 8 | 22638 | 1455 | 70904343 |
Irritability | 15.16 | 12.59 | 36 | 22610 | 38189 | 70867609 |
Secondary immunodeficiency | 14.76 | 12.59 | 10 | 22636 | 2879 | 70902919 |
Hypoxia | 14.74 | 12.59 | 64 | 22582 | 93280 | 70812518 |
Abortion induced | 14.58 | 12.59 | 14 | 22632 | 6611 | 70899187 |
Impaired healing | 14.55 | 12.59 | 3 | 22643 | 74371 | 70831427 |
Respiratory arrest | 14.51 | 12.59 | 44 | 22602 | 53889 | 70851909 |
Treatment failure | 14.23 | 12.59 | 15 | 22631 | 144127 | 70761671 |
Plasma cell myeloma | 14.22 | 12.59 | 3 | 22643 | 73198 | 70832600 |
Hyperhidrosis | 14.22 | 12.59 | 81 | 22565 | 131505 | 70774293 |
Accidental death | 14.19 | 12.59 | 11 | 22635 | 3897 | 70901901 |
Premature labour | 14.11 | 12.59 | 15 | 22631 | 7985 | 70897813 |
Neuropathy peripheral | 13.93 | 12.59 | 12 | 22634 | 126884 | 70778914 |
Mental disorder | 13.90 | 12.59 | 29 | 22617 | 28211 | 70877587 |
Premature separation of placenta | 13.88 | 12.59 | 7 | 22639 | 1165 | 70904633 |
Plethysmography | 13.71 | 12.59 | 3 | 22643 | 33 | 70905765 |
Myoclonic epilepsy | 13.38 | 12.59 | 8 | 22638 | 1856 | 70903942 |
Psychotic disorder | 13.35 | 12.59 | 34 | 22612 | 37667 | 70868131 |
Dyspepsia | 13.25 | 12.59 | 60 | 22586 | 89017 | 70816781 |
Arteriosclerosis | 13.18 | 12.59 | 21 | 22625 | 16617 | 70889181 |
Contusion | 13.00 | 12.59 | 13 | 22633 | 128023 | 70777775 |
Pre-eclampsia | 12.96 | 12.59 | 13 | 22633 | 6472 | 70899326 |
Application site warmth | 12.92 | 12.59 | 4 | 22642 | 181 | 70905617 |
Non-small cell lung cancer stage IIIB | 12.91 | 12.59 | 3 | 22643 | 44 | 70905754 |
COVID-19 | 12.88 | 12.59 | 9 | 22637 | 105748 | 70800050 |
None
Source | Code | Description |
---|---|---|
ATC | N07BA01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS DRUGS USED IN ADDICTIVE DISORDERS Drugs used in nicotine dependence |
FDA CS | M0014836 | Nicotine |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018679 | Cholinergic Agonists |
MeSH PA | D005731 | Ganglionic Stimulants |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018722 | Nicotinic Agonists |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D000077444 | Smoking Cessation Agents |
FDA EPC | N0000175706 | Cholinergic Nicotinic Agonist |
CHEBI has role | CHEBI:22917 | botanical insecticides |
CHEBI has role | CHEBI:35471 | psychotropic drugs |
CHEBI has role | CHEBI:35474 | anti-anxiety agents |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:47958 | muscarinic agonists |
CHEBI has role | CHEBI:49110 | peripheral nervous system drugs |
CHEBI has role | CHEBI:50846 | Immunologic factor |
CHEBI has role | CHEBI:50905 | teratogeno |
CHEBI has role | CHEBI:50910 | agente neurotoxico |
CHEBI has role | CHEBI:52290 | mitogens |
CHEBI has role | CHEBI:59163 | biological marker |
CHEBI has role | CHEBI:76924 | plant metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Nicotine dependence | indication | 56294008 | DOID:0050742 |
Smoking cessation assistance | indication | 384742004 | |
Pellagra | indication | 418186002 | DOID:8457 |
Niacin deficiency | indication | 418279001 | |
Nicotine Withdrawal Symptoms | indication | ||
Hyperlipidemia | off-label use | 55822004 | DOID:1168 |
Hypophosphatemia | contraindication | 4996001 | |
Alcoholism | contraindication | 7200002 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Esophagitis | contraindication | 16761005 | DOID:11963 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Temporomandibular joint disorder | contraindication | 41888000 | |
Low blood pressure | contraindication | 45007003 | |
Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
Thromboangiitis obliterans | contraindication | 52403007 | DOID:12918 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Prinzmetal angina | contraindication | 87343002 | |
Gout | contraindication | 90560007 | DOID:13189 |
Magnetic resonance imaging | contraindication | 113091000 | |
Liver function tests abnormal | contraindication | 166603001 | |
Angina pectoris | contraindication | 194828000 | |
Arterial hemorrhage | contraindication | 234003006 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Raynaud's phenomenon | contraindication | 266261006 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Pheochromocytoma | contraindication | 302835009 | |
Acute coronary syndrome | contraindication | 394659003 | |
Pharyngitis | contraindication | 405737000 | DOID:2275 |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial infarction in recovery phase | contraindication | 418044006 | |
Hypertensive urgency | contraindication | 443482000 | |
Life-Threatening Cardiac Arrhythmias | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.05 | Basic |
pKa2 | 3.14 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | AGONIST | Ki | 8.56 | WOMBAT-PK | CHEMBL | |||
Potassium voltage-gated channel subfamily D member 3 | Ion channel | IC50 | 7.40 | WOMBAT-PK | |||||
Cytochrome P450 2A6 | Enzyme | IC50 | 5.36 | WOMBAT-PK | |||||
Transient receptor potential cation channel subfamily A member 1 | Ion channel | ACTIVATOR | EC50 | 4.80 | IUPHAR | ||||
Neuronal acetylcholine receptor; alpha2/beta4 | Ion channel | Ki | 7.15 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha2/beta2 | Ion channel | Ki | 8.26 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | Ki | 5.95 | WOMBAT-PK | |||||
Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | Ki | 7.85 | WOMBAT-PK | |||||
Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | Ki | 7.64 | CHEMBL | |||||
Serotonin 3 (5-HT3) receptor | Ion channel | Ki | 4.15 | CHEMBL | |||||
Acetylcholine receptor; alpha1/beta1/delta/gamma | Ion channel | Ki | 5.83 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 | Ion channel | IC50 | 7.07 | CHEMBL | |||||
Acetylcholine receptor subunit alpha | Ion channel | IC50 | 4.68 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-3 | Ion channel | IC50 | 7.35 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 5.39 | WOMBAT-PK | |||||
Acetylcholine-binding protein | Unclassified | Ki | 7.20 | CHEMBL | |||||
Acetylcholine receptor subunit delta | Ion channel | Ki | 9 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | Ki | 9.03 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 6.89 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 6.61 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-9 | Ion channel | Kd | 8.30 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit beta-4 | Ion channel | Ki | 7.14 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-3 | Ion channel | Ki | 7.33 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-2 | Ion channel | Ki | 7.92 | CHEMBL | |||||
Soluble acetylcholine receptor | Unclassified | Ki | 7.52 | CHEMBL | |||||
Acetylcholine receptor subunit alpha | Ion channel | IC50 | 4.64 | CHEMBL | |||||
Lycopene cyclase | Enzyme | IC50 | 5.32 | CHEMBL | |||||
Nicotinic acetylcholine receptor alpha 5 subunit | Ion channel | Ki | 5.61 | CHEMBL | |||||
Acetylcholine receptor subunit beta-like 2 | Ion channel | Ki | 5.57 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | Ki | 8.72 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | IC50 | 8.15 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha2/beta2 | Ion channel | Ki | 8.26 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | Ki | 9 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | Ki | 6.70 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Kd | 9.40 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | Ki | 8.26 | CHEMBL | |||||
Neuronal acetylcholine receptor | Ion channel | Kd | 11 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha2/beta4 | Ion channel | Ki | 7.15 | CHEMBL | |||||
Acetylcholine receptor | Ion channel | Ki | 5.20 | CHEMBL | |||||
Muscarinic acetylcholine receptor | GPCR | IC50 | 4.55 | CHEMBL | |||||
Transient receptor potential cation channel subfamily A member 1 | Ion channel | EC50 | 5 | CHEMBL | |||||
Potassium voltage-gated channel subfamily D member 3 | Ion channel | BLOCKER | IC50 | 7.40 | IUPHAR |
ID | Source |
---|---|
4020286 | VUID |
N0000148163 | NUI |
D03365 | KEGG_DRUG |
4018610 | VANDF |
4020286 | VANDF |
C0028040 | UMLSCUI |
CHEBI:17688 | CHEBI |
NCT | PDB_CHEM_ID |
CHEMBL3 | ChEMBL_ID |
DB00184 | DRUGBANK_ID |
CHEMBL3989563 | ChEMBL_ID |
D009538 | MESH_DESCRIPTOR_UI |
89594 | PUBCHEM_CID |
2585 | IUPHAR_LIGAND_ID |
65-31-6 | SECONDARY_CAS_RN |
6M3C89ZY6R | UNII |
1306106 | RXNORM |
11529 | MMSL |
5173 | MMSL |
5174 | MMSL |
72003 | MMSL |
d00316 | MMSL |
001770 | NDDF |
003575 | NDDF |
323283001 | SNOMEDCT_US |
68540007 | SNOMEDCT_US |
77544001 | SNOMEDCT_US |
D061485 | MESH_DESCRIPTOR_UI |
CHEMBL1201536 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Nicotrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5400 | INHALANT | 4 mg | RESPIRATORY (INHALATION) | NDA | 29 sections |
Nicotrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5401 | SPRAY, METERED | 10 mg | NASAL | NDA | 28 sections |
Nicotrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5401 | SPRAY, METERED | 10 mg | NASAL | NDA | 28 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0029 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0053 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0170 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
good sense nicotinemint | HUMAN OTC DRUG LABEL | 1 | 0113-0206 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0344 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0422 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0456 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0532 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0704 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0713 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0734 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0749 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0761 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0854 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
good sense nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0873 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0957 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-1125 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
good sense nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-1190 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
good sense nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-1352 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7007 | LOZENGE | 4 mg | ORAL | ANDA | 14 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7008 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7029 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7124 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7170 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7190 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
Basic Care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7201 | LOZENGE | 2 mg | ORAL | ANDA | 14 sections |
Basic Care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7203 | LOZENGE | 4 mg | ORAL | ANDA | 14 sections |